Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP is anticipated to announce its Q1 2025 earnings results before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of $0.09 per share and revenue of $61.06 million for the quarter.
Aurinia Pharmaceuticals Price Performance
Shares of AUPH stock traded up $0.00 during trading on Tuesday, hitting $8.00. The company had a trading volume of 137,945 shares, compared to its average volume of 1,343,737. The firm has a market capitalization of $1.09 billion, a P/E ratio of -53.34 and a beta of 1.20. Aurinia Pharmaceuticals has a one year low of $4.92 and a one year high of $10.67. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The stock's 50-day moving average price is $8.00 and its 200 day moving average price is $8.16.
Insider Activity
In other news, insider Greg Keenan sold 8,305 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $8.23, for a total value of $68,350.15. Following the completion of the transaction, the insider now directly owns 153,484 shares in the company, valued at approximately $1,263,173.32. This trade represents a 5.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Joseph M. Miller sold 61,859 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $494,872.00. Following the completion of the transaction, the chief financial officer now owns 633,515 shares in the company, valued at $5,068,120. This represents a 8.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 343,898 shares of company stock valued at $2,753,094 in the last 90 days. Insiders own 4.30% of the company's stock.
Analysts Set New Price Targets
Separately, StockNews.com raised Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, March 27th.
Get Our Latest Stock Report on AUPH
About Aurinia Pharmaceuticals
(
Get Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
See Also
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
